Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT

Bone Marrow Transplantation

Volumn 47, Issue 4, 2012, Pages 562-567

  Molina, J R ^a   Serrano, J ^a   Sanchez Garcia J ^a   Rodriguez Villa A ^a   Gomez P ^a   Tallon D ^a   Martin V ^a   Rodriguez G ^a   Rojas, R ^a   Martin C ^a   Martinez F ^a   Lvarez, M A ^a   Torres, A ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

allo SCT; antifungal prophylaxis; children; voriconazole

Indexed keywords

CASPOFUNGIN; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADVERSE OUTCOME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HYPERTRANSAMINASEMIA; INFECTION PREVENTION; KIDNEY DYSFUNCTION; LIVER INJURY; LIVER VENOOCCLUSIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PANCREATITIS; PRESCHOOL CHILD; PRIMARY PREVENTION; PRIORITY JOURNAL; RASH; SCHOOL CHILD; SYSTEMIC MYCOSIS; TREATMENT DURATION; TREMOR; VISUAL DISORDER;

ACUTE DISEASE; ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HUMANS; MALE; MYCOSES; PYRIMIDINES; STEM CELL TRANSPLANTATION; TIME FACTORS; TRIAZOLES;

EID: 84859451336     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.111     Document Type: Article

References (34)

1. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant- Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-1100.
2. Rubio PM, Sevilla J, Gonzalez-Vicent M, Lassaletta A, Cuenca-Estrella M, Diaz MA et al. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: a retrospective single centre study. J Pediatr Hematol Oncol 2009; 31: 642-646.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate systematic review of literature. Clin Infect Dis 2001; 32: 358-366. (Pubitemid 32173620)
4. Leather JL, Wingard JR. New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Blood Rev 2006; 20: 267-287. (Pubitemid 44192562)
5. Dvorak CC, Steinbach WJ, Brown JM, Agarwal R. Risks and outcomes of invasive fungal infections in pediatric patients undergoing allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005; 36: 621-629. (Pubitemid 43115019)
6. Baddley JW, Andes DR, Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infec Dis 2010; 50: 1559-1567.
7. Thursky K, Byrnes G, Grigg A, Szer J, Slavin M. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 34: 115-121. (Pubitemid 39077101)
8. Steinbach WJ, Addison RM, McLAughlin L, Gerrald Q, Martin PL, Driscoll T et al. Prospective aspergillus galacto-mannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J 2007; 26: 558-564. (Pubitemid 47014154)
9. Hayden R, Pounds S, Knapp K, Petraitiene R, Schaufele RL, Sein T et al. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr Infect Dis J 2008; 27: 815-819.
10. Smith PB, Benjamin DK, Alexander BD, Johnson MD, Finkelman MA, Steinbach WJ. Quantification of 1,3-b-d-glucan levels in children: preliminary data for diagnostic use of the b-glucan assay in a pediatric setting. Clin Vaccine Immunol 2007; 14: 924-925.
11. Armenian AH, Nash KA, Kapoor N, Franklin JL, Gaynon PS, Ross LA et al. Prospective monitoring for invasive aspergillosis using galactomannan and polymerase chain reaction in high risk pediatric patients. J Pediatr Hematol Oncol 2009; 31: 920-926.
12. Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS et al. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 2010; 29: 415-420.
13. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242-1250. (Pubitemid 41534660)
14. Kanda Y, Yamamoto R, Chizuka A, Hamaki T, Suguro M, Arai C et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611-1625.
15. Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP et al. Patterns of susceptibility of aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol 2009; 47: 3271-3275.
16. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA et al. Itraconazole versus fluconazole for prevention of fangal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533. (Pubitemid 38168674)
17. Torres A, Serrano J, Rojas R, Martin V, Martin C, Tabares S et al. Voriconazole as primary antifungal prophylaxis in patients with neutropenia after hematopoietic stem cell transplantation or chemotherapy for acute myeloid leukemia. Eur J Haematol 2010; 84: 371-373.
18. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al. Posaconazole or fuconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347. (Pubitemid 46148776)
19. van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407-1416. (Pubitemid 39518200)
20. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR et al. Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoetic cell transplantation. Blood 2010; 115: 5111-5118.
21. Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB et al. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2010; 16: 1458-1462.
22. Roman E, Osunkwo I, Militano O, Cooney E, van de Ven C, Cairo MS. Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 2008; 50: 325-330.
23. Hugues WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T et al. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751. (Pubitemid 34194843)
24. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14. (Pubitemid 33152659)
25. de Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycosis Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-1821.
26. Sulahian A, Tabouret M, Ribaud P, Sarfati J, Gluckman E, Latge JP et al. Comparison of an enzyme immunoassay and a latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis 1996; 15: 139-145. (Pubitemid 26098500)
27. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-357. (Pubitemid 38692699)
28. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845-851.
29. Kolve H, Ahlke E, Fegeler W, Ritter J, Jurgens H, Groll AH. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J Antimicrob Chemother 2009; 64: 383-387.
30. Trifilio SM, Bennett CL, Yarnold PR, McKoy JM, Parada J, Mehta J et al. Breakthrough zygomycosis after voriconazole administration among patients with hematological malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-429. (Pubitemid 46487308)
31. Amigues I, Cohen N, Chung D, Seo SK, Plescia C, Jakubowski A et al. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 46-52.
32. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53: 935-944.
33. Groll AH, Kolve H, Ehlert K, Paulussen M, Vormoor J. Pharmacokinetic interaction between voriconazole and ciclo-sporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother 2004; 53: 113-114. (Pubitemid 38072193)
34. Kontoyiannis DP. Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success. Bone Marrow Transplant 2011; 46: 165-173.